¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"hormone like action"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • mass action
    Áú·®ÀÛ¿ë
  • nerve action potential
    ½Å°æÈ°µ¿ÀüÀ§
  • neurotropic action
    Çâ½Å°æÀÛ¿ë
  • photochemical action
    ±¤È­ÇÐÀÛ¿ë
  • polyphasic action potential
    ´Ù»óȰµ¿ÀüÀ§
  • primary action
    ÀÏÂ÷ÀÛ¿ë
  • promotor action
    ÃËÁøÀÛ¿ë
  • pharmacological action
    ¾à¸®ÀÛ¿ë
  • reflex action
    ¹Ý»çÀÛ¿ë
  • reverse action clasp
    ¿ªÀÛ¿ë°¥°í¸®
  • specific action
    ƯÀÌÀÛ¿ë
  • synergistic action
    »ó½ÂÀÛ¿ë
  • sensory nerve action potential
    °¨°¢½Å°æÈ°µ¿ÀüÀ§
  • serrated action potential
    Åé´ÏȰµ¿ÀüÀ§
  • antidiuretic hormone
    Ç×ÀÌ´¢È£¸£¸ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • reflex action
    ¹Ý»çÀÛ¿ë
  • specific action
    ƯÀÌÀÛ¿ë
  • synergistic action
    »ó½ÂÀÛ¿ë
  • thermogenic action
    ¹ß¿­ÀÛ¿ë
  • trigger action
    ¹æ¾Æ¼èÀÛ¿ë, À¯¹ßÀÛ¿ë
  • biphasic action potential
    ÀÌ»óȰµ¿ÀüÀ§
  • compound muscle action potential
    (¢¡muscle) º¹ÇÕ±ÙȰµ¿ÀüÀ§
  • compound nerve action potential
    (¢¡nerve) º¹ÇսŰæÈ°µ¿ÀüÀ§
  • reverse action clasp
    ¿ªÀÛ¿ë°¥°í¸®
  • monophasic action potential
    ´Ü»óȰµ¿ÀüÀ§
  • nerve action potential
    ½Å°æÈ°µ¿Àü¾Ð
  • polyphasic action potential
    ´Ù»óȰµ¿ÀüÀ§
  • sensory nerve action potential
    °¨°¢½Å°æÈ°µ¿ÀüÀ§
  • serrated action potential
    Åé´ÏȰµ¿ÀüÀ§
  • repeat action tablet
    ¹Ýº¹ÀÛ¿ë¾Ë¾à
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • gestagenic action
    ÇÁ·ÎÁ¦½ºÅ×·ÐÀÛ¿ë(¡­íÂéÄ).
  • immediate action
    Áï°¢ÀÛ¿ë, Áï½ÃÀÛ¿ë.
  • indirect action
    °£Á¢ÀÛ¿ë.
  • indirect action
    °£Á¢ÀÛ¿ë
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inotropic action
    º¯·ÂÀÛ¿ë(ܨÕôíÂéÄ), ¼öÃàÃËÁøÀÛ¿ë(â¥õêõµòäíÂéÄ).³»°ú¼öÃà·Â
  • inotropic action
    º¯·ÂÀÛ¿ë, ¼öÃàÃËÁøÀÛ¿ë.[³»°ú]¼öÃà·Â º¯µ¿ÀÛ¿ë.
  • pharmacodynamic action
    ¾à¿ªÇÐ(Àû) ÀÛ¿ë(å·æ³ùÊ(îÜ) íÂéÄ).
  • photochemical action
    ±¤È­ÇÐÀÛ¿ë(ÊÙËöËí).
  • photodynamic action
    ±¤¿ªÇÐÀÛ¿ë(ÎÃæ³ùÊ íÂéÄ).
  • physical action
    ¹°¸®Àû ÀÛ¿ë(¡­íÂéÄ).
  • physiological action
    »ý¸®ÀÛ¿ë(¡­íÂéÄ).
  • primary action
    ÀÏÂ÷±â´É
  • principle of least action
    ÃÖ¼ÒÀÛ¿ëÀÇ ¿ø¸®(õÌá´íÂéÄ¡­ê«ìµ).
  • prolonged action drug
    Áö¼Ó¼º ¾àÁ¦(ò¥áÙàõå·ð¥).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • thrush like patches
    ¾Æ±¸Ã¢¾ç ¹ÝÁ¡(¡­åÆÚèïÇ)
  • trypsin-like immunoreactivity(TLI)
  • yeast like
    È¿¸ð¾ç
  • yeast like fungus
    È¿¸ð»ó±Õ(ý£Ù½ßÒж), ÀÇ»çÈ¿¸ð±Õ(ëôÞÄý£Ù½Ð¶).
  • yeast like fungus
    È¿¸ð»ó±Õ(ý£Ù½ßÒж), ÀÇ»çÈ¿¸ð±Õ(ëôÞÄý£Ù½Ð¶).
  • absorption action
    Èí¼öÀÛ¿ë.
  • action myoclonia
    Ȱµ¿°£´ë¼º ±Ù°æ·Ã(Áõ)(¡­ÊàÓÛàõÐÉÌâÕýñø)
  • action myoclonia
    Ȱµ¿°£´ë¼º ±Ù°æ·Ã(Áõ)(¡­ÊàÓÛàõÐÉÌâÕýñø).
  • action potential
    Ȱµ¿ÀüÀ§(¡­ï³êÈ), Ȱµ¿Àü¾Ð(¡­ï³äâ)
  • action tremor
    ÇàÀ§ÁøÀü(ú¼êÓòÉïµ).
  • action, bactericidal
    »ì±ÕÀÛ¿ë
  • action, bacteriostatic
    Á¤±ÕÀÛ¿ë
  • additive action
    ºÎ°¡ÀÛ¿ë.
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • after action
    ÈÄ(¼Ó)(ý­(áÙ))ÀÛ¿ë.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • gonadotropic hormone
    ¼º¼±ÀÚ±Ø(àõàÍí©Ð½)È£¸£¸ó
  • gonadotropin releasing hormone
    °í³ªµµÆ®·ÎÇÉ ¹æÃâ(Û¯õó)È£¸£¸ó
  • growth hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó
  • hormone
    È£¸£¸ó
  • hypothalamic hormone
    ½Ã»óÇϺÎ(ãÊßÉù»Ý») È£¸£¸ó
  • interstitial cell hormone
    °£Áú¼¼Æ÷(Êàòõá¬øà) È£¸£¸ó
  • interstitial cell-stimulating hormone
    °£Áú¼¼Æ÷(Êàòõá¬øà)ÀÚ±Ø(í©Ð½) È£¸£¸ó
  • juvenile hormone
    ¼Ò¾Æ(á³ä®) È£¸£¸ó
  • lactogenic hormone
    ÃÖÀ¯(õÊêá)È£¸£¸ó
  • lightening hormone
    ¼¶±¤(àìÎÃ) È£¸£¸ó
  • lipotrophic hormone
    ÁöÁúÀÚ±Ø(ò·òõí©Ð½)È£¸£¸ó
  • lipotropic hormone
    ÁöÁúÀÚ±Ø(ò·òõí©Ð½) È£¸£¸ó
  • local hormone
    ±¹¼Ò(ÏÑá¶)È£¸£¸ó
  • luteotrophic hormone
    ȲüÀÚ±Ø(üÜô÷í©Ð½)È£¸£¸ó
  • luteotropic hormone
    ȲüÀÚ±Ø(üÜô÷í©Ð½)È£¸£¸ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
FRH follicle-stimulating hormone-releasing hormone
FSH-RH follicle-stimulating hormone-releasing hormone
GDH glucose dehydrogenase; glutamate dehydrogenase; glycerophosphate dehydrogenase; glycol dehydrogenase...
GH-RH growth hormone-releasing hormone
GHRHR growth hormone-releasing hormone receptor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
APA Action potential amplitude
APD Action potential duration
APD(50) Action potential duration
APD90 Action potential duration
APD(50) Action potential duration at 50
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • follicle stimulating hormone releasing factor
    ³­Æ÷ ÀÚ±Ø È£¸£¸ó ¹æÃâ ÀÎÀÚ
  • follicular hormone
    ¿©Æ÷ È£¸£¸ó
    ôÃßµ¿¹°ÀÇ ³­¼Ò ¾È¿¡ ÀÖ´Â ³­Æ÷¿¡¼­ ºÐºñµÇ´Â ÀÚ¼º È£¸£¸ó. ³­Æ÷ È£¸£¸ó, ¹ßÁ¤ È£¸£¸óÀ̶ó°íµµ ÇÑ´Ù. »ý½Ä±â¸¦ ¹ßÀ°½ÃŰ°í ±× ±â´ÉÀ» ³ªÅ¸³»µµ·Ï ÇÏ¿© Á¦2Â÷ ¶Ç´Â Á¦3Â÷ ¼ºÂ¡À» ¹ß´Þ½Ã۴µ¥, ƯÈ÷ Æ÷À¯·ù¿¡¼­ ¹ßÁ¤À» ÀÏÀ¸Å°°Ô ÇÏ´Â µ¥¼­ ¹ßÁ¤ È£¸£¸óÀ̶ó´Â À̸§ÀÌ ºÙ¾ú´Ù. ³­¼Ò À̿ܿ¡µµ ŹÝÀ» ºñ·ÔÇÏ¿© ºÎ½Å ÇÇÁúÀ̳ª Á¤¼Ò·ÎºÎÅÍ ¼Ò·® ºÐºñµÇ´Âµ¥ ¿¡½ºÆ®·ÐÀ̳ª ¿¡½ºÆ®¶óµð¿Ã ¹× ÀÎü¿¡¼­ º¼ ¼ö ÀÖ´Â ¿¡½ºÆ®¸®¿Ã µî 3Á¾·ùÀÇ ½ºÅ×·ÎÀ̵尡 ¾Ë·ÁÁ® ÀÖ´Ù. È­ÇÐÀûÀ¸·Î ¾ÈÁ¤µÇ¾î ÀÖÀ¸¸ç Àڱà ¹ßÀ°, ³»¸· Áõ½Ä, Á¥»ù ¹ßÀ°, ±ÔÄ¢Àû ¿ù°æ, Á¦2Â÷ ¼ºÂ¡ µîÀ» ÃËÁøÇÑ´Ù. ÀÌ È£¸£¸óÀÇ ºÐºñ´Â ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â ¿©Æ÷ ÀÚ±Ø È£¸£¸ó
  • hormone antagonist
    Ç×È£¸£¸ó ¾à, Ç×È£¸£¸ó ¹°Áú
  • hormone dependent tumor
    È£¸£¸ó ÀÇÁ¸¼º Á¾¾ç
  • hormone recenptor
    È£¸£¸ó ¼ö¿ëü
    È£¸£¸óÀÌ ÀÛ¿ëÇÏ´Â ºÎÀ§¿¡¼­ È£¸£¸óÀÌ °áÇÕÇÏ´Â °÷.
  • human growth hormone
    ¼ºÀå È£¸£¸ó
    ¼ºÀåÀ» ÃËÁøÇÏ´Â ¹°ÁúÀ» ÃÑĪÇϸç, ƯÈ÷ ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÀ» ¸»ÇÑ´Ù.
  • human thyroid stimulating hormone
    »ç¶÷ °©»ó¼± ÀÚ±Ø È£¸£¸ó
  • hypothalamic hormone
    ½Ã»ó ÇϺΠȣ¸£¸ó
  • hypothalamic hypophysiotropic hormone
    ½Ã»ó ÇϺμº Çâ³úÇϼöü¼º È£¸£¸ó
  • inhibitory hormone
    ¾ïÁ¦ È£¸£¸ó
    Ç¥Àû ±â°ü¿¡ ´ëÇÏ¿© ¾ïÁ¦ÀûÀ¸·Î ÀÛ¿ëÇϴ ȣ¸£¸ó.
  • lactation hormone
    ÃÖÀ¯ È£¸£¸ó
  • luteinizing hormone
    Ȳüȭ È£¸£¸ó, Ȳü Çü¼º È£¸£¸ó
  • luteotropic hormone
    Ȳü ÀÚ±Ø È£¸£¸ó
    Ȳü Çü¼ºÀ» ÀÚ±ØÇÏ´Â Çϼöü Àü¿± È£¸£¸ó.
  • lutinizing hormone
    Ȳüȭ È£¸£¸ó
  • male hormone
    ³²¼º È£¸£¸ó
    ³²¼º °íȯÀÇ °£ ¼¼Æ÷¿¡¼­ ºÐºñµÇ´Â ¾Èµå·Î°Õ. µ¿¹°ÀÇ ¿õ¼º È£¸£¸ó¿¡ ÇØ´çÇÏ´Â ¼º È£¸£¸óÀ¸·Î¼­, ºÎ¼º±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
pleuropneumonia-like organisms The original name given to a group of bacteria which did not possess cell walls; these organism's, isolated from man and other animals, soil, and sewage, are now assigned to the order Mycoplasmatales.
(05 Mar 2000)
corticotropin-like intermediate-lobe peptide <protein> A product of propiomelanocortin with unknown function.
Acronym: CLIP
(05 Mar 2000)
Csk-like protein-tyrosine kinase <enzyme> Phosphorylates c-terminal conserved tyr of src family members; from mouse brain; has 52% identity with mouse csk; mw 52 kD; genbank u05210
Registry number: EC 2.7.1.-
Synonym: ctk (kinase), ctk gene product, csk-type protein-tyrosine kinase, ntk (kinase), bhk (kinase)
(26 Jun 1999)
cyanobacterium-like bodies A Cryptosporidium-like genus of coccidian parasites reported from millipedes, reptiles, insectivores, and a rodent species. Cyclospora is characterised by acid-fast oocysts with two sporocysts, each with two sporozoites. Cyclospora species is an undescribed but distinct species of Cyclospora that is implicated as the cause of a widespread, prolonged but self-limited human diarrhoea in patients in North, Central, and South America; Caribbean countries; Southeast Asia; and eastern Europe previously reported as caused by cyanobacterium-like bodies.
Synonym: cyanobacterium-like bodies.
(05 Mar 2000)
hepatitis c-like viruses A genus of flaviviridae causing parenterally-transmitted non-a, non-b hepatitis (hepatitis c) which is associated with transfusions and drug abuse. Hepatitis c virus is the type species.
(12 Dec 1998)
Shiga like toxin <protein> Group of structurally related toxins that block eukaryotic protein synthesis by cleaving the 28S rRNA subunit of ribosomes.
Examples: Shiga toxin, Shiga like toxins SLT 1 and SLT 2 of Escherichia coli.
(18 Nov 1997)
SLE-like syndrome <syndrome> A disease with manifestations suggestive of systemic lupus erythematosus, without meeting diagnostic criteria for that disease; sometimes used for drug-induced lupus.
(05 Mar 2000)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
insulin like growth factor <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin.
They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present).
Insulin like growth factor I = somatomedin A = somatomedin C
Insulin like growth factor II = MSA (Multiplication stimulating activity).
Insulin like growth factor 1 is released from the liver in response to growth hormone.
Acronym: IGF
(18 Nov 1997)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
insulin-like growth factor-binding protein 2 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth factor binding protein 3 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin like growth-factor-binding protein 4 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á